
    
      In this Phase 3, double blind, vehicle-controlled study, patients will be admitted into this
      multi-center, double blind, randomized, vehicle controlled, parallel group pivotal study only
      after a written informed consent has been obtained and after all inclusion/exclusion criteria
      have been met. Male and female patients at least 9 years of age with facial acne vulgaris
      will be eligible for enrollment for daily treatment with S6G5T-3 or its vehicle S6G5T-8, for
      12 weeks
    
  